Please login to the form below

Not currently logged in
Email:
Password:

checkpoint inhibitor

This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

administered selective complement component 5a receptor inhibitor. ... In addition to Tavneos, the acquisition gives Amgen access to three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral

Latest news

More from news
Approximately 11 fully matching, plus 225 partially matching documents found.

Latest Intelligence

  • Putting the ovation into innovation: trends from ESMO Putting the ovation into innovation: trends from ESMO

    Based on the results we have seen with immune checkpoint inhibitors (ICIs), it will be interesting to see how T-DXd performs in the neoadjuvant setting. ... However, the data is very impressive in patients no longer responding to checkpoint inhibitor

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Immune checkpoint inhibitors. Immune (T) cells exhibit proteins that can turn an immune response on or off, called checkpoint proteins. ... Several checkpoint inhibitor drugs have been developed showing strong event- free survival and PFS rates, opening

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    These compounds could be used to tackle resistance to kinase inhibitor drugs, for example. ... The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...